{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:29:07Z","timestamp":1786703347628,"version":"build-2736575974"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>Plasma cell myeloma (PCM) is the second most common haematological malignancy and accounts for 1% of all hematological tumors. PCM remains a challenging disease to treat because of its heterogeneity. Despite therapeutic advances, a significant proportion of patients do not respond to treatment or develop resistance, highlighting the need to identify reliable predictive biomarkers. Recent research suggests that non-coding RNAs (ncRNAs), i.e., microRNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA) are important regulators of gene expression and play a key role in the pathogenesis. Epigenetic changes precede genetic and protein modifications, and the analysis of a single ncRNA can reflect the status of several genes. Moreover, ncRNAs are stable and can be detected in a minimally invasive manner using readily available biological samples. This review synthesizes current preclinical and clinical data on ncRNAs as predictive biomarkers of response to PCM therapies, identifies the most promising molecules and their mechanisms of action, highlights key methodological limitations, and proposes a translational validation framework necessary for clinical implementation. The most promising candidates are miR-21, lncRNA: MALAT1, and PCAT-1, which are well established in the literature and confirmed at both the mechanistic and clinical levels. However, small cohorts, heterogeneity of studies, and lack of methodological standardization limit the strength of this evidence, highlighting the need for prospective multicenter studies with standardized analytical procedures.<\/jats:p>","DOI":"10.3389\/or.2026.1868835","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:37:56Z","timestamp":1786700276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-coding RNAs as predictive factors of oncological outcomes in plasma cell myeloma"],"prefix":"10.3389","volume":"20","author":[{"given":"Alicja","family":"Bogdanowicz-\u017bele\u017aniak","sequence":"first","affiliation":[{"name":"Department of Laboratory Diagnostics, Medical University of Lublin","place":["Lublin, Poland"]},{"name":"Doctoral School, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Moniczewska","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, Medical University of Lublin","place":["Lublin, Poland"]},{"name":"Doctoral School, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Korpysz","sequence":"additional","affiliation":[{"name":"Department of Biochemical Diagnostics, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Szudy-Szczyrek","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Mlak","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1586\/14737159.2014.946906","article-title":"The potential of miRNAs as biomarkers for multiple myeloma","volume":"14","author":"Rocci","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/cancers11111738","article-title":"The role and function of microRNA in the pathogenesis of multiple myeloma","volume":"11","author":"Handa","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/cancers11020236","article-title":"Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma","volume":"11","author":"Amodio","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.7150\/jca.35098","article-title":"Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways","volume":"10","author":"Shen","year":"2019","journal-title":"J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1080\/15384101.2020.1839701","article-title":"Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p\/JAG1 axis","volume":"19","author":"Wang","year":"2020","journal-title":"Cell Cycle"},{"key":"B10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.18502\/ijph.v53i3.15137","article-title":"Multiple myeloma and occupational risk factors: a narrative review","volume":"53","author":"Hejrati","year":"2024","journal-title":"Iran J Public Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e850","DOI":"10.1002\/iid3.850","article-title":"Biological research on the occurrence and development of multiple myeloma and its treatment","volume":"11","author":"Wu","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5603\/AHP.2021.0004","article-title":"Clinical implications of cytogenetic and molecular aberrations in multiple myeloma","volume":"52","author":"Goldman-Mazur","year":"2021","journal-title":"Acta Haematol Pol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101910","DOI":"10.1016\/j.eclinm.2023.101910","article-title":"SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of biomarker-defined early multiple myeloma\u2014a systematic review with meta-analysis","volume":"58","author":"Ludwig","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1096852","DOI":"10.3389\/fonc.2022.1096852","article-title":"Experts\u2019 consensus on the definition and management of high risk multiple myeloma","volume":"12","author":"Marcon","year":"2023","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/cells13100853","article-title":"Multiple myeloma: the role of autologous stem cell transplantation in the era of immunotherapy","volume":"13","author":"Rocchi","year":"2024","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1413825","DOI":"10.3389\/fmed.2024.1413825","article-title":"CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey","volume":"11","author":"Hakan","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","article-title":"Targeted immunotherapy: harnessing the immune system to battle multiple myeloma","volume":"10","author":"Xu","year":"2024","journal-title":"Cell Death Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: a journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","article-title":"Perspectives on the treatment of multiple myeloma","volume":"29","author":"Rafae","year":"2024","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3324\/haematol.2024.285893","article-title":"Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States","volume":"110","author":"Hultcrantz","year":"2025","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/2643-3230.BCD-25-0292","article-title":"The two sides of bispecific antibodies in multiple myeloma: where trial promise meets real-world practice","volume":"6","author":"Zweegman","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3892\/etm.2023.12170","article-title":"Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma","volume":"26","author":"Zhang","year":"2023","journal-title":"Exp Ther Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1398902","DOI":"10.3389\/fonc.2024.1398902","article-title":"Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma","volume":"14","author":"Miller","year":"2024","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1755","DOI":"10.1002\/cnr2.1755","article-title":"Identifying monoclonal gammopathy of undetermined significance from electronic health records","volume":"6","author":"Tanenbaum","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/ijms24043136","article-title":"Monoclonal antibodies: the greatest resource to treat multiple myeloma","volume":"24","author":"De Luca","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","volume-title":"Recommendations of the Polish Myeloma Group for the Diagnosis and Treatment of Multiple Myeloma and Other Plasma Cell Dyscrasias for 2025","author":"Giannopoulos","year":"2025"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3324\/haematol.2023.284662","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5603\/AHP.a2023.0024","article-title":"Role of flow cytometric measurable residual disease assessment in multiple myeloma","volume":"54","author":"Krzywdzi\u0144ska","year":"2023","journal-title":"Acta Haematol Pol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1182\/blood-2019-125134","article-title":"MRD evaluation by PET\/CT according to Deauville criteria combined with multiparameter flow cytometry in newly diagnosed transplant-eligible multiple myeloma patients enrolled in the phase II randomized FORTE trial","volume":"134","author":"Zamagni","year":"2019","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/ijms20092249","article-title":"Digital PCR in myeloid malignancies: ready to replace quantitative PCR?","volume":"20","author":"Cilloni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40364-023-00469-6","article-title":"Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma","volume":"11","author":"Li","year":"2023","journal-title":"Biomark Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3324\/haematol.2023.283831","article-title":"Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients","volume":"109","author":"Mithraprabhu","year":"2024","journal-title":"Haematologica"},{"key":"B41","unstructured":"Plasma cell neoplasms (including multiple myeloma) treatment (PDQ\u00ae)\u2013health professional version"},{"key":"B42","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/gb-2009-10-6-r64","article-title":"A novel and universal method for microRNA RT-qPCR data normalization","volume":"10","author":"Mestdagh","year":"2009","journal-title":"Genome Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nmeth.3014","article-title":"Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study","volume":"11","author":"Mestdagh","year":"2014","journal-title":"Nat Methods"},{"key":"B44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"188491","DOI":"10.1016\/j.bbcan.2020.188491","article-title":"Non-coding RNAs and potential therapeutic targeting in cancer","volume":"1875","author":"Toden","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10142-022-00947-4","article-title":"Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets","volume":"23","author":"Loganathan","year":"2023","journal-title":"Funct Integr Genomics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","article-title":"Functional classification and experimental dissection of long noncoding RNAs","volume":"172","author":"Kopp","year":"2018","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12929-019-0523-z","article-title":"The emerging roles and functions of circular RNAs and their generation","volume":"26","author":"Yu","year":"2019","journal-title":"J Biomed Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","article-title":"Non-coding RNAs in disease: from mechanisms to therapeutics","volume":"25","author":"Nemeth","year":"2024","journal-title":"Nat Rev Genet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3892\/ijo.2023.5517","article-title":"Long non-coding RNAs in multiple myeloma","volume":"62","author":"Yang","year":"2023","journal-title":"Int J Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"107593","DOI":"10.1016\/j.leukres.2024.107593","article-title":"Roles of noncoding RNAs in multiple myeloma","volume":"146","author":"Lei","year":"2024","journal-title":"Leuk Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol Biomed"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2217\/bmm-2022-0349","article-title":"Role of ncRNA in multiple myeloma","volume":"16","author":"Leng","year":"2022","journal-title":"Biomark Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1186\/1471-2407-14-809","article-title":"MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression","volume":"14","author":"Cho","year":"2014","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e23400","DOI":"10.1002\/jcla.23400","article-title":"Long non-coding RNA T-cell factor 7 in multiple myeloma: a potential biomarker for deteriorated clinical features and poor prognosis","volume":"34","author":"Zhang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B57","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4149\/neo_2021_210205N184","article-title":"LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN","volume":"68","author":"Yang","year":"2021","journal-title":"Neoplasma"},{"key":"B58","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3390\/molecules29030721","article-title":"The role of the PTEN tumor suppressor gene and its anti-angiogenic activity in melanoma and other cancers","volume":"29","author":"Maphutha","year":"2024","journal-title":"Molecules"},{"key":"B59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/16078454.2021.1872275","article-title":"Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma","volume":"26","author":"Yin","year":"2021","journal-title":"Hematology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3892\/or.2022.8410","article-title":"Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib-based treatment response and survival via the microRNA-608-mediated Wnt\/\u03b2-catenin pathway","volume":"48","author":"Li","year":"2022","journal-title":"Oncol Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-018-0615-3","article-title":"Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential","volume":"11","author":"Spaan","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B62","first-page":"9932","article-title":"The role of Wnt\/\u03b2-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma","volume":"13","author":"Yuan","year":"2021","journal-title":"Am J Transl Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"106785","DOI":"10.1016\/j.leukres.2022.106785","article-title":"MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner","volume":"114","author":"Liu","year":"2022","journal-title":"Leuk Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/15548627.2019.1635380","article-title":"MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4","volume":"16","author":"Wu","year":"2020","journal-title":"Autophagy"},{"key":"B65","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3892\/or.2016.5318","article-title":"hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10","volume":"37","author":"Xi","year":"2017","journal-title":"Oncol Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41419-019-1551-z","article-title":"Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b","volume":"10","author":"Fu","year":"2019","journal-title":"Cell Death Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1080\/15384101.2019.1662257","article-title":"Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt\/\u03b2-catenin signaling pathway","volume":"18","author":"Li","year":"2019","journal-title":"Cell Cycle"},{"key":"B68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41419-018-1219-0","article-title":"LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p","volume":"10","author":"Pan","year":"2019","journal-title":"Cell Death Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/s41375-018-0104-2","article-title":"Targeting the MALAT1\/PARP1\/LIG3 complex induces DNA damage and apoptosis in multiple myeloma","volume":"32","author":"Hu","year":"2018","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-981-13-1426-1_6","article-title":"Circular RNAs act as miRNA sponges","volume":"1087","author":"Panda","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrg.2016.20","article-title":"Endogenous microRNA sponges: evidence and controversy","volume":"17","author":"Thomson","year":"2016","journal-title":"Nat Rev Genet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jnr.24356","article-title":"The interaction of circRNAs and RNA binding proteins: an important part of circRNA maintenance and function","volume":"98","author":"Zang","year":"2020","journal-title":"J Neurosci Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/CAD.0000000000001378","article-title":"Circ_0005615 contributes to the progression and bortezomib resistance of multiple myeloma by sponging miR-185-5p and upregulating IRF4","volume":"33","author":"Fu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e3329","DOI":"10.1002\/jgm.3329","article-title":"Inhibition of hsa_circ_0003489 shifts balance from autophagy to apoptosis and sensitizes multiple myeloma cells to bortezomib via miR-874-3p\/HDAC1 axis","volume":"23","author":"Tian","year":"2021","journal-title":"J Gene Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"118506","DOI":"10.1016\/j.lfs.2020.118506","article-title":"CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p\/PRKCD axis in multiple myeloma","volume":"262","author":"Liu","year":"2020","journal-title":"Life Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3390\/ijms25116065","article-title":"Circulating miR-16 and miR-21 levels in multiple myeloma: prognostic significance of survival and response to lenalidomide treatment","volume":"25","author":"Gkioka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers11050731","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"11","author":"Chong","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.3390\/cancers13174365","article-title":"miR-22 modulates lenalidomide activity by counteracting MYC addiction in multiple myeloma","volume":"13","author":"Caracciolo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.21037\/tcr-24-1543","article-title":"PARP1 promotes tumor proliferation in lenalidomide-resistant multiple myeloma via the downregulation of microRNA-192-5p-AKT signaling","volume":"13","author":"Luo","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.3324\/haematol.2017.168070","article-title":"Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma","volume":"102","author":"Jung","year":"2017","journal-title":"Haematologica"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e23924","DOI":"10.1002\/jcla.23924","article-title":"Baseline lncRNA PCAT1 high expression and its longitudinal increment during induction therapy predict worse prognosis in multiple myeloma patients","volume":"35","author":"Zhao","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1111\/jcmm.15035","article-title":"PCAT-1 promotes cell growth by sponging miR-129 via MAP3K7\/NF-\u03baB pathway in multiple myeloma","volume":"24","author":"Shen","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3109\/10428194.2011.591004","article-title":"Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation","volume":"52","author":"Wang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B86","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/cancers12040782","article-title":"Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma","volume":"12","author":"Ronchetti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/cancers14102348","article-title":"The multiple myeloma landscape: epigenetics and non-coding RNAs","volume":"14","author":"Coira","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nature09284","article-title":"OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma","volume":"467","author":"Medina","year":"2010","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","first-page":"101984","DOI":"10.18632\/oncotarget.21957","article-title":"LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR-509-5p to modulate FOXP1 expression","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"B90","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bjh.14882","article-title":"Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma","volume":"179","author":"Handa","year":"2017","journal-title":"Br J Haematol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/carcin\/bgs333","article-title":"miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1756-8722-4-37","article-title":"Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug resistance in myeloma cells","volume":"4","author":"Hao","year":"2011","journal-title":"J Hematol Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000486662","article-title":"Comparative analysis of miRNA expression profiles of multiple myeloma with 1q21 gains and normal FISH","volume":"139","author":"Cui","year":"2018","journal-title":"Acta Haematol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5315\/wjh.v5.i2.51","article-title":"Role of microRNA in regulation of myeloma-related angiogenesis and survival","volume":"5","author":"Rahat","year":"2016","journal-title":"World J Hematol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10238-025-02015-0","article-title":"Long non-coding RNAs and therapeutic resistance in multiple myeloma: from molecular insights to clinical applications","volume":"26","author":"Safari","year":"2026","journal-title":"Clin Exp Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/mc.22626","article-title":"Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant","volume":"56","author":"Poi","year":"2017","journal-title":"Mol Carcinog"},{"key":"B97","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3892\/ol.2020.12390","article-title":"Long non-coding RNA T cell factor 7 is associated with increased disease risk and poor prognosis in multiple myeloma","volume":"21","author":"Ding","year":"2021","journal-title":"Oncol Lett"},{"key":"B98","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3892\/ol.2021.12673","article-title":"LncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma","volume":"21","author":"Liu","year":"2021","journal-title":"Oncol Lett"},{"key":"B99","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/cancers16010084","article-title":"Epigenetic alterations as vital aspects of bortezomib molecular action","volume":"16","author":"Kulig","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.3390\/ijms21207539","article-title":"Role of microRNAs in diagnosis, prognosis and management of multiple myeloma","volume":"21","author":"Soliman","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/ijo.2021.5185","article-title":"LncRNA ST3GAL6-AS1 promotes invasion by inhibiting hnRNPA2B1-mediated ST3GAL6 expression in multiple myeloma","volume":"58","author":"Shen","year":"2021","journal-title":"Int J Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.7150\/ijms.98156","article-title":"Recent progress of circRNAs in hematological malignancies","volume":"21","author":"Cui","year":"2024","journal-title":"Int J Med Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1373\/clinchem.2014.221341","article-title":"Circulating microRNA biomarker studies: pitfalls and potential solutions","volume":"61","author":"Witwer","year":"2015","journal-title":"Clin Chem"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1868835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:37:58Z","timestamp":1786700278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1868835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":103,"alternative-id":["10.3389\/or.2026.1868835"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1868835","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1868835"}}